Warnex Inc.

Warnex Inc.

October 03, 2006 07:00 ET

Warnex Receives NPIP Approval For Salmonella Test

LAVAL, QC, Oct. 3 - Warnex Inc. (TSX:WNX) today announced that its
Salmonella test used with the Warnex™ Rapid Pathogen Detection System has
been approved by the U.S. Department of Agriculture's (USDA) National Poultry
Improvement Plan (NPIP).

The objective of the National Poultry Improvement Plan is to provide a
cooperative industry-state-federal program through which new technology can be
effectively applied to the improvement of poultry and poultry products. The
plan consists of a variety of programs intended to prevent and control poultry
diseases.

The Warnex Salmonella test for environmental samples was independently
validated by NPIP-approved laboratories, which concluded that the Warnex test
performed as well as or better than the two NPIP-approved microbiological
reference methods. In addition, the test performed just as well with pooled
samples, which can increase a plant's testing efficiency and significantly
reduce testing costs.

"Our new sample pooling feature clearly illustrates our commitment to
innovation aimed at improving our clients' efficiency," said Mark Busgang,
President and CEO of Warnex. "This, in addition to NPIP approval which
provides further regulatory and scientific validation of our tests, will help
reduce the barrier to entry for major poultry clients and encourage adoption."

The Warnex Rapid Pathogen Detection System offers a versatile detection
and quantification platform, using real-time PCR technology combined with
proprietary genetic markers and software, to rapidly and accurately determine
the presence of pathogens in a sample. The system allows for the simultaneous
detection of multiple pathogens and processing of samples within 3 to
48 hours, a significant improvement over traditional microbiology tests that
require 5 to 7 days.

According to the U.S. Centers for Disease Control and Prevention (CDC),
an estimated 1.4 million cases and 500 deaths occur in the United States
annually due to Salmonella infections. Salmonellosis, an infection caused by
eating food contaminated with Salmonella, causes symptoms such as diarrhea,
fever, vomiting and abdominal cramps, lasting usually 4 to 7 days. In some
cases, it may cause blood infection and even death, if untreated.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc., Laval, Quebec.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, integration of acquisitions, manufacturing and
laboratory facilities, suppliers, key employees, key customers and business
partners, financial resources and credit risk, government regulations, foreign
currency risk and volatility of share price, and other important factors that
could cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the second
quarter ended June 30, 2006, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.

Contact Information